November 2026 — Artificial intelligence is moving deeper into wearable health devices, with regulators clearing new AI-powered monitoring tools and venture capital flowing into cardiac wearables.
1. AI Arrhythmia Model Cleared by FDA
Belfast-based medtech company PulseAI has received U.S. FDA 510(k) clearance for its AI-powered arrhythmia analysis model designed for wearables. The model integrates with compatible ECG devices, sends recordings for automated cloud analysis, and returns structured results for clinical review.
In a prospective study of 296 participants published in Heart Rhythm, the algorithm improved atrial fibrillation (AFib) detection sensitivity while reducing inconclusive interpretations by 92% compared with the native watch algorithm, according to the company.
2. Cardiac Wearable Startups Keep Attracting Funding
U.S. startup Skribe raised a USD 1.6 million seed round led by SeaX, with participation from GoAhead Ventures and Marin Sonoma Impact Ventures. Its Aurora system combines a multi-sensor adhesive patch with AI analysis to estimate left ventricular ejection fraction, with home monitoring as a longer-term goal. The system was selected for the FDA's READI-Home Innovation Challenge.
3. AI Wearable Monitoring Market on Fast Growth Track
The AI in wearable health monitoring market was valued at USD 2.80 billion in 2025 and is projected to reach USD 18.22 billion by 2035, at a CAGR of 20.60%, driven by rising burdens of atrial fibrillation, hypertension and sleep apnea, wider ownership of smartwatches, rings and patches, and growing regulatory authorization for wearable rhythm and diagnostic tools.
4. FDA Continues Device Classification Updates
Separately, the FDA finalized classifications for additional wearable and non-invasive devices: the wearable vibration device for orthopedic use and the external mechanical stimulator for relief of congestion, both placed into Class II with special controls, providing clear regulatory pathways and reasonable assurance of safety and effectiveness.
Outlook
The common thread across these moves is continuous, AI-assisted monitoring moving from consumer fitness tracking toward clinically validated care. For suppliers of pulse oximeters, ECG sensors, vital-signs monitors and compatible accessories, demand for accurate, reliable remote-monitoring components is expected to keep expanding.
SaferLife Products Co., Ltd. supplies pulse oximeters, patient monitors and vital-signs accessories to distributors worldwide, supporting the growing demand for home and clinical monitoring.